ABSTRACT
In the fourth year of the COVID-19 occurrence, a new COVID-19 variant, JN.1, has emerged and spread globally and become the dominant strain in several regions. It has some specific mutations in its spike proteins, empowering it with higher transmissibility. Regarding the significance of the issue, understanding the clinical and immunological traits of JN.1 is critical for enhancing health strategies and vaccination efforts globally, with the ultimate goal of bolstering our collective response to the pandemic. In this study, we take a look at the latest findings of JN.1 characteristics and mutations as well as its consequences on bypassing immune system. We demonstrate the importance of continual surveillance and strategic adaptation within healthcare frameworks along with the significance of wastewater sampling for the rapid identification of emerging SARS-CoV-2 variants.
Disclosure statement
No potential conflict of interest was reported by the authors.
Abbreviations
ACE2 Angiotensin-Converting Enzyme 2
BTI Breakthrough Infection
CDC Centers for Disease Control and Prevention
COVID-19 Coronavirus Disease 2019
GISAID Global Initiative on Sharing All Influenza Data
hNEC Human Nasal Epithelial Cells
ICU Intensive Care Unit
INSACOG Indian SARS-CoV-2 Genomics Consortium
NT50 50% Neutralization Titer
RBD Receptor-binding motif
RBM Receptor-binding domain
SNAs Serum Neutralizing Antibodies
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2
SNPs Single Nucleotide Polymorphisms
VOI Variant of Interest
WHO World Health Organization
Author’s Contributions
MKH and MNA prepared the first draft. RE and AB revised the manuscript and prepared the final version. The project ran under the supervision of RE and all authors reviewed the final manuscript.